ClinicalTrials.gov
public full text
Public Domain
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
This phase II trial studies how well trebananib works in treating patients with advanced angiosarcoma that cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma#829279
- Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma#908839
- Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma#850343
- Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery#896131
- Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer#1115232
Record · ID 879730
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive